Can a new chemo combo beat the standard for HER2-Negative breast cancer?
Disease control
Completed
This phase III trial is testing whether a combination of docetaxel and cyclophosphamide works as well as or better than anthracycline-based chemotherapy (like doxorubicin) for women with HER2-negative breast cancer that has spread to lymph nodes or is high-risk. The study aims to…
Phase 3 • Sponsor: NSABP Foundation Inc • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC